ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Design an Efficient Multi-Epitope Peptide Vaccine Candidate Against SARS-CoV-2: An in silico Analysis

Yazdani, Zahra; Rafiei, Alireza*; Yazdani, Mohammadreza; Valadan, Reza
Infection and Drug Resistance2020DOI: 10.2147/IDR.S264573
32被引3阅读
引用收藏
分享

摘要

Background: To date, no specific vaccine or drug has been proven to be effective against SARS-CoV-2 infection. Therefore, we implemented an immunoinformatic approach to design an efficient multi-epitopes vaccine against SARS-CoV-2. Results: The designed-vaccine construct consists of several immunodominant epitopes from structural proteins of spike, nucleocapsid, membrane, and envelope. These peptides promote cellular and humoral immunity and interferon-gamma responses. Also, these epitopes have a high antigenic capacity and are not likely to cause allergies. To enhance the vaccine immunogenicity, we used three potent adjuvants: Flagellin of Salmonella enterica subsp. enterica serovar Dublin, a driven peptide from high mobility group box 1 as HP-91, and human beta-defensin 3 protein. The physicochemical and immunological properties of the vaccine structure were evaluated. The tertiary structure of the vaccine protein was predicted and refined by Phyre2 and Galaxi refine and validated using RAMPAGE and ERRAT. Results of ElliPro showed 246 sresidues from vaccine might be conformational B-cell epitopes. Docking of the vaccine with toll-like receptors (TLR) 3, 5, 8, and angiotensin-converting enzyme 2 approved an appropriate interaction between the vaccine and receptors. Prediction of mRNA secondary structure and in silico cloning demonstrated that the vaccine can be efficiently expressed in Escherichia coli. Conclusion: Our results demonstrated that the multi-epitope vaccine might be potentially antigenic and induce humoral and cellular immune responses against SARS-CoV-2. This vaccine can interact appropriately with the TLR3, 5, and 8. Also, it has a high-quality structure and suitable characteristics such as high stability and potential for expression in Escherichia coli.

学科与关键词

关键词
SARS-CoV-2multi-epitope vaccinestructural proteinshumoral immunitycellular immunityadjuvant
相关
加载中…
  • Immunoinformatics design of B and T-cell epitope-based SARS-CoV-2 peptide vaccination
    Khan, Muhammad Shehzad; Khan, Ibrar Muhammad; Ahmad, Syed Umair; Rahman, Ishrat; Khan, Muhammad Zahoor; Khan, Muhammad Shah Zeb; Abbas, Zain; Noreen, Shumaila; Liu, Yong*Frontiers in Immunology, 2023, 13: 1001430.
  • Anti-COVID-19 multi-epitope vaccine designs employing global viral genome sequences
    Zaheer, Tahreem; Waseem, Maaz; Waqar, Walifa; Dar, Hamza Arshad; Shehroz, Muhammad; Naz, Kanwal; Ishaq, Zaara; Ahmad, Tahir; Ullah, Nimat; Bakhtiar, Syeda Marriam; Muhammad, Syed Aun; Ali, Amjad*PEErJ, 2020, 8: e9541.被引 16
  • In-silico design of a new multi-epitope vaccine candidate against SARS-CoV-2
    Alibakhshi, Abbas*; Alagheband Bahrami, Armina; Mohammadi, Elmira; Ahangarzadeh, Shahrzad*; Mobasheri, MeysamActa Virologica, 2024, 67: 12481.被引 4
查看全部 →

发表信息

论文状态
公开发表
期刊
Infection and Drug Resistance
发表日期
2020
卷期
第 13 卷
页码
3007-3022
DOI
10.2147/IDR.S264573
期刊收录
NSL.SCIE
期刊等级
3区
成果收录
SCIE
资助标注
Research and Technology deputy of Mazandaran University of Medical Sciences [7252]

作者

  • Y

    Yazdani, Zahra (第一作者)

  • R

    Rafiei, Alireza (通讯)

查看全部 4 位作者收起作者
  • Y

    Yazdani, Mohammadreza

  • V

    Valadan, Reza

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417